logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Figure INF-4. Trends in HIV prevalence among injecting drug users estimated from national and sub-national samples, 2001 to 2005


Countries shown are where the average trend of available data is above 5%

Differences between countries should be interpreted with caution owing to different types of settings and/or study methods; national sampling strategies vary.

Data for Italy and Portugal and part of the data for France include non-IDUs and therefore may underestimate prevalence among IDUs.

Data for Belgium, Italy and Portugal are limited to prevalence among IDUs in treatment and may not be representative of prevalence among IDUs who are not in treatment. In addition, data may not be representative for people who are in treatment - this is known to be the case for Belgium.

Data for France, and part of the data for Belgium, are based on self-reported test results, which are less reliable than clinically-documented tests.

* Sweden: data from Stockholm;

France: data from 12 cities in France;

Spain: National data, excl. communities of Madrid and La Rioja

** Belgium: data from French Community


SB2006: Figure INF-4 part (i)

See also 'General notes for interpreting data' on the Explanatory notes and help page


Reitox National Focal Points

Page last updated: Wednesday, 21 November 2007